UNLABELLED: In this observational study, we found a positive relationship between low calcidiol levels and the risk of aortic calcification progression. A 10-ng/mL increase of calcidiol was associated with a decrease in the risk of progression by 44%. This figure was higher than that observed if we increased age by 10 years. INTRODUCTION: The aim of this study was to investigate the relationship between serum calcidiol levels and the onset and progression of aortic calcifications in a community-based sample of ambulatory subjects. METHODS: Three hundred two men and women aged 50 and over underwent two lateral X-rays and were followed up for 4 years. Abdominal aortic calcifications were classified as absent, mild-moderate, and severe. The biochemical measurements of serum calcium, phosphorus, parathyroid hormone, total alkaline phosphatase, tartrate-resistant acid phosphatase, creatinine, calcidiol, calcitriol, and osteocalcin were determined. Subjects who had received anti-osteoporotic treatments were excluded from the analysis. RESULTS: Subjects with progression of aortic calcifications had significantly lower serum calcidiol levels than those without progression. In the multivariate analysis, using the agreed upon serum levels for calcidiol (>30 ng/mL) as the reference, those subjects with calcidiol levels between 10 and 20 ng/mL showed a higher risk of progression of aortic calcification (odds ratio (OR) = 3.95; 95% confidence interval (CI) = 1.16 to 13.40). An even higher OR was observed in subjects with calcidiol values <10 ng/mL (OR = 4.10; 95% CI = 1.12 to 14.99). In addition, an increase by 1 ng/mL in osteocalcin levels was associated with a 17% reduction of the risk of aortic calcification progression. CONCLUSIONS: An increase by 10 ng/mL of calcidiol was associated with a decrease in the risk of aortic calcifications progression by 44%. This figure was even higher than that observed if we increased age by 10 years. Levels of calcidiol higher than 30 ng/mL seem to be desirable to reduce the progression of aortic calcification and to maintain bone turnover.
UNLABELLED: In this observational study, we found a positive relationship between low calcidiol levels and the risk of aortic calcification progression. A 10-ng/mL increase of calcidiol was associated with a decrease in the risk of progression by 44%. This figure was higher than that observed if we increased age by 10 years. INTRODUCTION: The aim of this study was to investigate the relationship between serum calcidiol levels and the onset and progression of aortic calcifications in a community-based sample of ambulatory subjects. METHODS: Three hundred two men and women aged 50 and over underwent two lateral X-rays and were followed up for 4 years. Abdominal aortic calcifications were classified as absent, mild-moderate, and severe. The biochemical measurements of serum calcium, phosphorus, parathyroid hormone, total alkaline phosphatase, tartrate-resistant acid phosphatase, creatinine, calcidiol, calcitriol, and osteocalcin were determined. Subjects who had received anti-osteoporotic treatments were excluded from the analysis. RESULTS: Subjects with progression of aortic calcifications had significantly lower serum calcidiol levels than those without progression. In the multivariate analysis, using the agreed upon serum levels for calcidiol (>30 ng/mL) as the reference, those subjects with calcidiol levels between 10 and 20 ng/mL showed a higher risk of progression of aortic calcification (odds ratio (OR) = 3.95; 95% confidence interval (CI) = 1.16 to 13.40). An even higher OR was observed in subjects with calcidiol values <10 ng/mL (OR = 4.10; 95% CI = 1.12 to 14.99). In addition, an increase by 1 ng/mL in osteocalcin levels was associated with a 17% reduction of the risk of aortic calcification progression. CONCLUSIONS: An increase by 10 ng/mL of calcidiol was associated with a decrease in the risk of aortic calcifications progression by 44%. This figure was even higher than that observed if we increased age by 10 years. Levels of calcidiol higher than 30 ng/mL seem to be desirable to reduce the progression of aortic calcification and to maintain bone turnover.
Authors: Heike A Bischoff-Ferrari; Edward Giovannucci; Walter C Willett; Thomas Dietrich; Bess Dawson-Hughes Journal: Am J Clin Nutr Date: 2006-07 Impact factor: 7.045
Authors: M Naves; J B Díaz-López; C Gómez; A Rodríguez-Rebollar; M Rodríguez-García; J B Cannata-Andía Journal: Osteoporos Int Date: 2003-04-25 Impact factor: 4.507
Authors: Yamini S Levitzky; L Adrienne Cupples; Joanne M Murabito; William B Kannel; Douglas P Kiel; Peter W F Wilson; Philip A Wolf; Christopher J O'Donnell Journal: Am J Cardiol Date: 2008-02-01 Impact factor: 2.778
Authors: Carlos Gómez-Alonso; Manuel L Naves-Díaz; Jose L Fernández-Martín; Jose B Díaz-López; Maria T Fernández-Coto; Jorge B Cannata-Andía Journal: Kidney Int Suppl Date: 2003-06 Impact factor: 10.545
Authors: Craig R Walsh; L Adrienne Cupples; Daniel Levy; Douglas P Kiel; Marian Hannan; Peter W F Wilson; Christopher J O'Donnell Journal: Am Heart J Date: 2002-10 Impact factor: 4.749
Authors: Pawel Szulc; Terri Blackwell; Douglas P Kiel; John T Schousboe; Jane Cauley; Teresa Hillier; Marc Hochberg; Nicolas Rodondi; Brent C Taylor; Dennis Black; Steven Cummings; Kristine E Ensrud Journal: Bone Date: 2015-06-24 Impact factor: 4.398
Authors: D Tuñón-Le Poultel; J B Cannata-Andía; P Román-García; J B Díaz-López; E Coto; C Gómez; M Naves-Díaz; I Rodríguez Journal: Osteoporos Int Date: 2013-11-27 Impact factor: 4.507
Authors: Pawel Szulc; Terri Blackwell; John T Schousboe; Douglas C Bauer; Peggy Cawthon; Nancy E Lane; Steven R Cummings; Eric S Orwoll; Dennis M Black; Kristine E Ensrud Journal: J Bone Miner Res Date: 2014-04 Impact factor: 6.741
Authors: Jorge B Cannata-Andía; Augusto Díaz-Sottolano; Pehuén Fernández; Manuel Naves-Díaz; Walter Douthat; José L Fernández-Martín; Carmen Palomo-Antequera; Pablo Herrero-Puente; Ricardo Mouzo; Natalia Carrillo-López; Sara Panizo; Guillermo H Ibañez; Carlos A Cusumano; Carolina Ballarino; Vicente Sánchez-Polo; Jacqueline Pefaur-Penna; Irene Maderuelo-Riesco; Jesús Calviño-Varela; Mónica D Gómez; Carlos Gómez-Alonso; John Cunningham Journal: BMC Med Date: 2022-02-18 Impact factor: 8.775
Authors: Jordi Bover; Armando Aguilar; Carolt Arana; Pablo Molina; María Jesús Lloret; Jackson Ochoa; Gerson Berná; Yessica G Gutiérrez-Maza; Natacha Rodrigues; Luis D'Marco; José L Górriz Journal: Front Med (Lausanne) Date: 2021-05-19